Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Kenji MorimotoTadaaki YamadaTakayuki TakedaShinsuke ShiotsuKoji DateNobuyo TamiyaYasuhiro GotoHibiki KandaYusuke ChiharaYusuke KunimatsuYuki KatayamaMasahiro IwasakuShinsaku TokudaKoichi TakayamaPublished in: Targeted oncology (2023)
UMIN000044049.